Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Bio-Logical and Pharmacological Profiling

Nadine Álvarez(Hackensack Meridian Health), David S. Perlin(Center for Discovery), David B. Olsen, John A. McCauley(Fox Chase Cancer Center), Valerie W. Shurtleff(United States Military Academy), Risha Rasheed(Hackensack Meridian Health), Nicholas G. Fox(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Steven Park(Hackensack Meridian Health), Andrew M. Nelson(Hackensack Meridian Health), Carolyn Bahnck-Teets(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. E. Layton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Craig A. Parish(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gregory C. Adam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tamara D. Cabalu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Krista Getty(Merck & Co., Inc., Rahway, NJ, USA (United States)), John F. Fay(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Howe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoyan Zhou(Affiliated Hospital of Shaanxi University of Chinese Medicine), Todd Mayhood(Merck & Co., Inc., Rahway, NJ, USA (United States)), Enriko Dolgov(Hackensack Meridian Health), Christine Burlein(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vijeta Sharma(Hackensack Meridian Health), Christopher W. Boyce(Scripps Research Institute), Imad Salhab(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fatima Nizar(Hackensack Meridian Health), Khushboo Sahay(Hackensack Meridian Health), Daniel V. Iwamoto(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matthew Zimmerman(Hackensack Meridian Health), Shih Lin Goh(Merck & Co., Inc., Rahway, NJ, USA (United States))
Preprints.org
June 19, 2024
Cited by 1


Related Papers